UMIN ID: UMIN000000637
Registered date:16/03/2007
Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | non-small cell lung cancer |
| Date of first enrollment | 2007/02/01 |
| Target sample size | 20 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Autologous Lymphocyte-Activated Killer cells (LAK) Gefitinib |
Outcome(s)
| Primary Outcome | Overall survival |
|---|---|
| Secondary Outcome | Survival rate Progression-free survival Antitumor effect Improvement of tumor-related markers QOL(FACT-BRM) Safety |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 80years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Patients who have: previous history of hypersensitivity to Gefitinib, uncontrolled infections, active autoimmune diseases, and serious cardiac disease; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study. |
Related Information
| Primary Sponsor | Juntendo University, School of Medicine |
|---|---|
| Secondary Sponsor | Shinyokohama medical clinic |
| Source(s) of Monetary Support | Medinet Co.,Ltd. |
| Secondary ID(s) |
Contact
| public contact | |
| Name | |
| Address | 2-1-1 Hongo,Bunkyo-Ku,Tokyo Japan |
| Telephone | 03-5802-1063 |
| Affiliation | Juntendo University, School of Medicine Department of Respiratory Medicine |
| scientific contact | |
| Name | Kazuhisa Takahashi |
| Address | 2-1-1 Hongo,Bunkyo-Ku,Tokyo Japan |
| Telephone | 03-5802-1063 |
| Affiliation | Juntendo University, School of Medicine Department of Respiratory Medicine |